$4.62 Billion is the total value of Avidity Partners Management LP's 85 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Exit | SCIENCE 37 HOLDINGS INC | $0 | – | -430,000 | -100.0% | -0.01% | – | |
| PHAS | Exit | PHASEBIO PHARMACEUTICALS INC | $0 | – | -4,361,365 | -100.0% | -0.02% | – |
| Exit | SEMA4 HOLDINGS CORP | $0 | – | -950,000 | -100.0% | -0.02% | – | |
| ONCS | Exit | ONCOSEC MED INC | $0 | – | -2,945,000 | -100.0% | -0.03% | – |
| Exit | TANGO THERAPEUTICS INC | $0 | – | -813,700 | -100.0% | -0.06% | – | |
| BLSA | Exit | BCLS ACQUISITION CORP | $0 | – | -500,000 | -100.0% | -0.10% | – |
| Exit | ERASCA INC | $0 | – | -982,500 | -100.0% | -0.16% | – | |
| SPNE | Exit | SEASPINE HLDGS CORP | $0 | – | -2,010,000 | -100.0% | -0.23% | – |
| STOK | Exit | STOKE THERAPEUTICS INC | $0 | – | -891,100 | -100.0% | -0.23% | – |
| TMDX | Exit | TRANSMEDICS GROUP INC | $0 | – | -300,000 | -100.0% | -0.26% | – |
| IOVA | Exit | IOVANCE BIOTHERAPEUTICS INC | $0 | – | -1,382,900 | -100.0% | -0.27% | – |
| ATEC | Exit | ALPHATEC HLDGS INC | $0 | – | -1,715,000 | -100.0% | -0.30% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -1,450,000 | -100.0% | -0.35% | – |
| SIBN | Exit | SI-BONE INC | $0 | – | -996,700 | -100.0% | -0.35% | – |
| BGNE | Exit | BEIGENE LTDsponsored adr | $0 | – | -132,000 | -100.0% | -0.36% | – |
| NKTX | Exit | NKARTA INC | $0 | – | -1,414,082 | -100.0% | -0.38% | – |
| COGT | Exit | COGENT BIOSCIENCES INC | $0 | – | -1,357,700 | -100.0% | -0.41% | – |
| NGM | Exit | NGM BIOPHARMACEUTICALS INC | $0 | – | -1,798,100 | -100.0% | -0.48% | – |
| CNC | Exit | CENTENE CORP DEL | $0 | – | -432,400 | -100.0% | -0.68% | – |
| SYK | Exit | STRYKER CORPORATION | $0 | – | -184,700 | -100.0% | -0.76% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INC | $0 | – | -844,000 | -100.0% | -1.17% | – |
| ALNY | Exit | ALNYLAM PHARMACEUTICALS INC | $0 | – | -288,500 | -100.0% | -1.17% | – |
| SGEN | Exit | SEAGEN INC | $0 | – | -445,500 | -100.0% | -1.24% | – |
| CTLT | Exit | CATALENT INC | $0 | – | -940,000 | -100.0% | -1.38% | – |
| AVTR | Exit | AVANTOR INC | $0 | – | -4,522,600 | -100.0% | -1.80% | – |
| HZNP | Exit | HORIZON THERAPEUTICS PUB L | $0 | – | -1,482,200 | -100.0% | -1.86% | – |
| ANTM | Exit | ELEVANCE HEALTH INC | $0 | – | -207,600 | -100.0% | -1.92% | – |
| HUM | Exit | HUMANA INC | $0 | – | -212,000 | -100.0% | -2.09% | – |
| XBI | Exit | SPDR SER TRs&p biotech | $0 | – | -1,480,000 | -100.0% | -2.39% | – |
| BIIB | Exit | BIOGEN INC | $0 | – | -600,000 | -100.0% | -3.26% | – |
| Exit | SPDR SER TRcall | $0 | – | -4,052,000 | -100.0% | -6.53% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC | 15 | Q3 2023 | 4.6% |
| ARVINAS INC | 14 | Q3 2023 | 4.9% |
| ZENTALIS PHARMACEUTICALS INC | 14 | Q3 2023 | 4.8% |
| SYNDAX PHARMACEUTICALS INC | 14 | Q3 2023 | 3.2% |
| IDEAYA BIOSCIENCES INC | 13 | Q3 2023 | 2.5% |
| NATERA INC | 13 | Q3 2023 | 1.9% |
| ALPINE IMMUNE SCIENCES INC | 13 | Q3 2023 | 0.5% |
| ABBVIE INC | 12 | Q2 2023 | 9.7% |
| HORIZON THERAPEUTICS PUB LTD | 12 | Q3 2022 | 3.4% |
| AVANTOR INC | 11 | Q1 2023 | 6.0% |
View Avidity Partners Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adicet Bio, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2023 | 1,888,887 | 4.0% |
| ESSA Pharma Inc. | February 14, 2023 | 1,855,400 | 4.2% |
| Gritstone bio, Inc. | February 14, 2023 | 2,859,971 | 3.3% |
| IVERIC bio, Inc. | February 14, 2023 | 838,407 | 0.6% |
| ONCOSEC MEDICAL IncSold out | February 14, 2023 | 0 | 0.0% |
| PhaseBio Pharmaceuticals Inc | February 14, 2023 | 2,040,000 | 4.1% |
| Phathom Pharmaceuticals, Inc. | February 14, 2023 | 1,900,000 | 4.6% |
| Viridian Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Anika Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Avidity Partners Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-09 |
| SC 13G | 2024-03-27 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Avidity Partners Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.